Merck & Co (Merck & Co Inc.)’s oral drug molnupiravir could reduce the death or need for hospitalization in serious patients by 50 percent. On Friday, it was claimed by the company that the results of this oral drug have turned out to be very good in the interim clinical trial. Merck and its partner company Ridgeback Biotherapeutics will try to get emergency use rights in the US as soon as possible. Due to the positive results of the drug, its Phase 3 trial is being stopped on the recommendation of external observers. Merck has said that it will prepare 10 million courses of this drug by the end of this year. Going forward, their number will be increased further.
This medicine will change the discussion about treatment of corona: Merck
Announcing the positive results of the trial, the Merck CEO told Reuters that the drug would change the ongoing debate about the treatment of COVID-19. If it is allowed, Molnupiravir will become the first oral antiviral drug of COVID-19, designed to make mistakes in the genetic code of the corona virus.
Paras Defense and Space gave bumper returns to investors, investors got so much profit on the very first day
Pfizer and Roche are also making antibody cocktails
Merck found in its interim analysis that 7.3 percent of those who were given molanupiravir either died or had to be hospitalized after 29 days of treatment. In comparison, 14.1 of the patients who were given placebo died or had to be hospitalized. Merck’s competitor company Pfizer and Swiss pharma company Roche are also in the race to prepare a similar drug for COVID. This will be an antibody cocktail that will be administered intravenously to the body of patients who have not been admitted to the hospital.
Get Business News ,, latest India News ,, and other breaking news on share market, investment scheme and much more on Business Khabar. Like us on Facebook, Follow us on Twitter for latest financial news and share market updates.
.